This randomized, double-blind, parallel-group study will assess the efficacy and safety of RoActemra/Actemra (tocilizumab) versus adalimumab in combination with methotrexate in patients with moderate to severe active rheumatoid arthritis. Patients will be randomized to receive either RoActemra/Actemra 8 mg/kg intravenously (iv) every 4 weeks plus placebo subcutaneously (sc) every 2 weeks or adalimumab 40 mg sc every 2 weeks plus placebo iv every 4 weeks. All patients will receive methotrexate (10-25 mg weekly) and folate (at least 5 mg weekly). The anticipated time on study treatment is 24 weeks.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01283971?cond=%22Arthritis%22&lup_s=07/14/2011&lup_d=30
